ORCA
Online Research @ CardiffÂ
Browse by Current Cardiff authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 3.
Morgan, Robert D., Porter, Catharine  ORCID: https://orcid.org/0000-0003-1851-0677, Zhou, Cong, Kristeleit, Rebecca, Desai, Sudha, White, Ann, Casbard, Angela C. ORCID: https://orcid.org/0000-0001-6241-3052, Humphrys, Alys, Swettenham, Jennifer B., Nixon, Lisette ORCID: https://orcid.org/0000-0002-1270-6970, Brogden, Elena, Powell, Wendy E. ORCID: https://orcid.org/0000-0002-4670-1406, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990 and Carucci, Margherita
2026.
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.
EClinicalMedicine
96
, 104012.
10.1016/j.eclinm.2026.104012
|
|
Murphy, Alexander D, Porter, Catharine ORCID: https://orcid.org/0000-0003-1851-0677, White, Ann, Irving, Alys, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Ray, Ruby, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Mahmood, Reem D., Karanth, Suman, Zhou, Cong, Pugh, Julia, Wheeler, Chelsey, Roberts, Victoria, Arnetoli, Giorgio, Salih, Zena, Hasan, Jurjees, Mitchell, Claire, Morgan, Robert D., Clamp, Andrew R. and Jayson, Gordon C.
2024.
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
International Journal of Gynecological Cancer
34
, pp. 1034-1040.
10.1136/ijgc-2024-005455
|
|
|
|
Jayson, G., Carucci, Margherita, Hurt, Christopher ORCID: https://orcid.org/0000-0003-1206-8355, Zhou, Cong, Monaghan, Phillip, Wych, Julie, Irving, Alys, Narasimham, Monica, Morrison, Hilary, Campbell, Sue, Glasspool, Rosalind, Longo, Mirella ORCID: https://orcid.org/0000-0002-9867-3806, Nelson, Annmarie ORCID: https://orcid.org/0000-0002-6075-8425, Dive, Caroline, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243 and Clamp, Andrew
2021.
VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer.
Presented at: NCRI Cancer Conference,
Virtual,
2021.
|
|